Free tool
FAERS Monitor: Allegra-D 12 Hour Allergy and Congestion
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020786 or its brand name (Allegra-D 12 Hour Allergy and Congestion, Fexofenadine Hydrochloride, Pseudoephedrine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
49
Serious
12
24% of reports
Hospitalization
8
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product quality issue8
- drug ineffective7
- diarrhoea4
- dizziness4
- extra dose administered4
- headache4
- nausea4
- chest discomfort2
- constipation2
- ear pain2
- fatigue2
- gastrointestinal disorder2
- hypersensitivity2
- insomnia2
- malaise2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2012 | 2 |
| 2014 | 11 |
| 2015 | 13 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 3 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 5 |
| 2026 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,110 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ear pain | 2 | 44.2 | 11.4 | 47 |
| extra dose administeredSignal | 4 | 42.4 | 16.6 | 123 |
| product quality issueSignal | 8 | 25.3 | 13.4 | 164 |
| gastrointestinal disorder | 2 | 9.6 | 2.5 | 8 |
| chest discomfort | 2 | 8.4 | 2.2 | 7 |
| hypersensitivity | 2 | 4.6 | 1.2 | 3 |
| constipation | 2 | 3.9 | 1.0 | 2 |
| dizzinessSignal | 4 | 3.4 | 1.3 | 5 |
| insomnia | 2 | 3.2 | 0.8 | 1 |
| headache | 4 | 2.7 | 1.1 | 3 |
| diarrhoea | 4 | 2.7 | 1.0 | 3 |
| drug ineffectiveSignal | 7 | 2.3 | 1.1 | 4 |
| nausea | 4 | 2.2 | 0.8 | 2 |
| malaise | 2 | 2.0 | 0.5 | 0 |
| fatigue | 2 | 1.1 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.